ALQGC.PA
Quantum Genomics Société Anonyme [ALQGC.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALQGC.PA Stock Summary
In the News
ALQGC.PA Financial details
Company Rating
-
Market Cap
3.96M
Income
-28.11M
Revenue
1.31M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
26 May 2024
P/E
0
Forward P/E
-
PEG
-
P/S
5.98
P/B
-
P/C
-
P/FCF
-0.18
Quick Ratio
0.61
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-87.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.06%
Revenue last 5Y
-63.47%
Revenue Q/Q
-
EPS Q/Q
-40.28%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
-367%
ROC
-4.5%
Gross Margin
-4777%
Oper. Margin
-4973%
Profit Margin
-4617%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0804-0.195
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
115.44K
Volume
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.714
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0721
Change
0%
Company Profile
- Volume Average 115.44K
- Market Capitalization 3.96M
- Employee 3
- CEO Dr. Jean-Philippe Milon Ph.D.
- Headquarters Paris,FR
- IPO Date 2010-05-28
-
Website
https://www.quantum-genomics.com 
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
